A 10 day old infant with pulmonary atresia, ventricular septal defect, and collateral pulmonary blood supply through a left sided ductus arteriosus developed complete shunt thrombosis four days after the creation of a modified BlalockTaussig shunt. Recombinant tissue plasminogen activator was given locally into the proximal end of the shunt as two bolus injections of 01I mg/kg and two bolus injections of 0-2 mglkg over 10 minutes, followed by a continuous infusion of 1-4 mglkglday for 16 hours and 0 7 mglkgiday for 18 hours with systemic low dose heparin 5 IU/kgIh. This resulted in complete clot dissolution and reperfusion without haemorrhagic complications and without laboratory signs of systemic fibrinolytic activation. (Br HeartJ' 1994;72:201-202) Recombinant tissue plasminogen activator is an effective thrombolytic agent that preferentially activates fibrin bound plasminogen and has a shorter plasma half life than streptokinase and urokinase.1-3 Data on the use and the dose regimens of recombinant tissue plasminogen activator for thrombolysis in children are few." We report the successful use of recombinant tissue plasminogen activator for the treatment of a thrombosed modified Blalock-Taussig shunt in a 10 day old infant. ligated. Four days later the child developed progressive cyanosis. The results of echocardiography and cardiac catheterisation showed a completely thrombosed Blalock-Taussig shunt (fig 1) .
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